Analytical and clinical validation of a novel in-house deep-sequencing method for minimal residual disease monitoring in a phase II trial for multiple myeloma
暂无分享，去创建一个
N. Puig | A. Oriol | N. Gutiérrez | B. Paiva | J. Bargay | N. Gutiérrez | I. Rapado | J. San-Miguel | J. Bladé | J. Lahuerta | R. García-Sanz | L. Rosiñol | M. Hernandez | C. Jiménez | M. Mateos | M. Cedena | J. Martínez-López | S. Barrio | R. Ayala | Y. Ruiz-Heredia | B. Sánchez-Vega | A. Teruel | R. Martínez | I. Rapado | R. Alonso | I. Cuenca | M. Martín-Ramos | M. Hernández | C. Marin | J. Martínez‐López | B. Sánchez-Vega | Isabel Cuenca | Carlos Marin | Cecilia Jiménez